145 related articles for article (PubMed ID: 25739417)
1. RE: Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis.
Qi X; Ji LJ; Zhang X; Ma Y; Ma W
J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25739417
[No Abstract] [Full Text] [Related]
2. Making sense of dual HER2-targeting in early breast cancer?
Carey LA; Barry W
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25224563
[No Abstract] [Full Text] [Related]
3. Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis.
Nagayama A; Hayashida T; Jinno H; Takahashi M; Seki T; Matsumoto A; Murata T; Ashrafian H; Athanasiou T; Okabayashi K; Kitagawa Y
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25224562
[TBL] [Abstract][Full Text] [Related]
4. Response.
Nagayama A; Hayashida T; Jinno H; Takahashi M; Kitagawa Y
J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25739418
[No Abstract] [Full Text] [Related]
5. Neoadjuvant chemotherapy with HER2 inhibitors for breast cancer.
Brede-Hekimian K
Lancet; 2012 Jun; 379(9833):2237; author reply 2238. PubMed ID: 22704161
[No Abstract] [Full Text] [Related]
6. Neoadjuvant chemotherapy with HER2 inhibitors for breast cancer.
Fujita T
Lancet; 2012 Jun; 379(9833):2237; author reply 2238. PubMed ID: 22704160
[No Abstract] [Full Text] [Related]
7. Dual HER2 targeting for early breast cancer.
Johnston SR
Lancet Oncol; 2013 Nov; 14(12):1145-6. PubMed ID: 24095298
[No Abstract] [Full Text] [Related]
8. Dual inhibition of HER2 in breast cancer treatment.
Gnant M; Steger GG
Lancet; 2012 Feb; 379(9816):596-8. PubMed ID: 22257672
[No Abstract] [Full Text] [Related]
9. [HER2-positive breast cancer: standard and double targeted therapy].
Semiglazov VF; Bozhok AA; Semiglazova TIu; Vasil'ev AG; Manikhas AG; Semiglazov VV; Bessonov AA; Nikolaev KS
Vopr Onkol; 2013; 59(3):341-6. PubMed ID: 23909035
[TBL] [Abstract][Full Text] [Related]
10. Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: one more step toward chemotherapy-free therapy.
Prat A; Baselga J
J Clin Oncol; 2013 May; 31(14):1703-6. PubMed ID: 23569319
[No Abstract] [Full Text] [Related]
11. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Guarneri V; Dieci MV; Frassoldati A; Maiorana A; Ficarra G; Bettelli S; Tagliafico E; Bicciato S; Generali DG; Cagossi K; Bisagni G; Sarti S; Musolino A; Ellis C; Crescenzo R; Conte P
Oncologist; 2015 Sep; 20(9):1001-10. PubMed ID: 26245675
[TBL] [Abstract][Full Text] [Related]
12. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
[TBL] [Abstract][Full Text] [Related]
13. Pertuzumab (Perjeta) for preoperative use in HER2-positive breast cancer.
Med Lett Drugs Ther; 2013 Dec; 55(1431):98-9. PubMed ID: 24322664
[No Abstract] [Full Text] [Related]
14. Hints of future progress for HER-2 breast cancer.
Twombly R
J Natl Cancer Inst; 2011 Apr; 103(7):535-7. PubMed ID: 21436059
[No Abstract] [Full Text] [Related]
15. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
16. Targeted treatments for breast cancer: a step forward.
Bachelot T; Tredan O
Lancet Oncol; 2013 May; 14(6):438-9. PubMed ID: 23602602
[No Abstract] [Full Text] [Related]
17. [A meta-analysis of neoadjuvant chemotherapy combined with trastuzumab for HER2-positive breast cancers].
Liao N; Zhang GC; Li XR; Yao M; Wang K
Nan Fang Yi Ke Da Xue Xue Bao; 2009 May; 29(5):943-5. PubMed ID: 19460715
[TBL] [Abstract][Full Text] [Related]
18. HER2-positive breast cancer.
Loibl S; Gianni L
Lancet; 2017 Jun; 389(10087):2415-2429. PubMed ID: 27939064
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]